SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Cash
SCI Pharmtech Inc
Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Cash
NT$134.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-2%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Cash
NT$1.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Cash
NT$1.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
23%
|
CAGR 10-Years
12%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Cash
NT$167.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Cash
NT$6B
|
CAGR 3-Years
56%
|
CAGR 5-Years
36%
|
CAGR 10-Years
19%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Cash
NT$923.2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Cash?
Cash
134.3m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Cash amounts to 134.3m TWD.
What is SCI Pharmtech Inc's Cash growth rate?
Cash CAGR 10Y
-2%
Over the last year, the Cash growth was -85%. The average annual Cash growth rates for SCI Pharmtech Inc have been -24% over the past three years , -10% over the past five years , and -2% over the past ten years .
You don't have any saved screeners yet